MAD Cohort 1 Begins. MAD Cohort 1 begins seven-day dosing period.

SAD Cohort 5 Completed. SAD Cohort 5B doses subjects; Cohort 5 has finished.

SAD Cohort 5 Underway. SAD Cohort 5A doses subjects.

SAD Cohort 4 doses subjects; Cohort 4 has finished.

Marissa Mazzolini hired as Reven’s Medical Affairs Manager.

Reven announced today that Peter Pacult has been promoted to the position of Senior Director of Clinical Operations. Mr. Pacult’s role will focus on leading Reven’s clinical efforts. In addition, Dane Baruzini has been promoted to Senior Director of Commercial … Read More

SAD Cohort 3 doses subjects; Cohort 3 has finished.

SAD Cohort 2 doses subjects; Cohort 2 has finished.

SAD Cohort 1B doses subjects; Cohort 1 has finished.

Reven’s Phase 1 Clinical Trial Begins. Reven doses their first subjects (Cohort 1A) under open IND successfully kicking off Phase 1 Clinical Trial.

Izabela Kawczynski hired as Project Manager.

Reven selects a United States based CMO to handle drug GMP drug manufacturing and development.

Phase 1 protocol approved by the IRB giving Reven the green light for their Phase 1 study in San Antonio.

Reven Hires Vincent Vanderbent. Vincent Vanderbent hired as Reven’s Director of Corporate Communications.

Dr. Scott E. Woodman joins Reven’s Advisory Board   Click Here for CV – SCOTT_WOODMAN_CV_05_06_2018